Capstone Therapeutics (CAPS) Misses Q2 EPS by 16c
Tweet
Share
E-mailGet Alerts CAPS Hot Sheet
Join SI Premium – FREE
Capstone Therapeutics (NASDAQ: CAPS) reported Q2 EPS of ($0.13), $0.16 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $12.85 million versus the consensus estimate of $15.05 million.
For earnings history and earnings-related data on Capstone Therapeutics (CAPS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Worthington Industries (WOR) Misses Q4 EPS by 9c
- BTIG Reiterates Buy Rating on Verastem (VSTM)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
